Submitted for publication December 23, 1996 Local recurrence of sarcoma is due to residual tumor cells remaining alter surgical resection and is associated with decreased survival. We implemented adenoviral-mediated transfer of the herpes simplex thymidine kinase (HSTK) gene with subsequent ganciclovir (GCV) administration to treat a model of residual sarcoma.
[3H]Thymidine uptake in MCA sarcoma cells was determined alter infection with replication incompetent adenovirus of the AdMLP .HSTK construct in the presence of GCV. In vivo efficacy was evaluated in a model of residual sarcoma when 9 mg of MCA tumor was implanted into the latissimus muscle of Fischer 344 rats. Three days alter implantation, animals were randomized to receive AdMLP .HSTK, AdCMV .Null, or viral suspension buffer intratumorally.
From Day 4, animals were administered b.i.d. GCV (50 mgikg) or saline ip. Tumors were excised on Day 14 and weighed. Statistical analysis was by Mann-Whitney U test. In vitro: [3HJ-thymidine incorporation was significantly decreased in MCA sarcoma cells infected with AdMLP .HSTK in the presence of GCV (P < 0.05). In vivo: Growth of MCA sarcoma treated with AdMLP.HSTK and GCV was significantly inhibited.
Final tumor weights in the AdMLP .HSTR/GCV group were lower than all control groups (P < 0.05). A significant antitumor growth effect on MCA sarcoma was seen with adenoviral-mediated transfer of the HSTK gene and GCV administration, both in vitro and in an in vivo model ofresidual disease. This prodrug gene therapy strategy warrants investigation as an adjuvant modality in the management of sarcoma. @ 1997 Academic Press
INTRODUCTION
Local recurrente of soft tissue sarcoma poses a significant clinical problem and is associated with decreased survival [1, 2] . Multimodality therapy has reduced the incidence of local recurrence but rates remain high [3] . Patients with retroperitoneal sarcoma treated with resectional surgery can have a 40% rate of local recurrence [4] . Local recurrence in patients with extremity sarcoma treated with limb sparing surgery and adjuvant brachytherapy ranges from 10 to 35% [3] . Local recurrence in both the abdomen and extremity is due to residual tumor cells remaining after surgical resection and adjuvant treatment. This study explored the local application of prodrug gene therapy to the growth ofMCA sarcoma in a model ofresidual disease.
Prodrug gene therapy for cancer involves the activationofan anticancer agent via the expression ora foreign transferred gene. We utilized an adenovirus vector to transfer the herpes simplex viTal thymidine kinase (HSTK) gene. Adenovirus has been used to transfer foreign genes into mammalian cells to affect tumor growth in multiple animal models [5] [6] [7] . Adenovirus can be genetically engineered to be replication incompetent and to contain up to a 7.5-kb exogenous gene. Adenoviral infection generates a strong inflammatory response and this may be helpful in eliciting an immune response toward tumor cells [8] .
Transfer of the HSTK gene with subsequent ganciclovir (GCV) administration yields cell death via a mechanism described in 1986 [9] . Expression of the HSTK gene produces the viTal enzyme (HSTK), which monophosphorylates the nucleoside analog prodrug GCV. Mammalian cellular enzymes then triphosphorylate the monophosphorylated GCV. The incorporation of triphosphorylated GCV into DNA results in chain termination and ultimately causes cell death [10] . An observed phenomenon associated with the HSTK/ GCV paradigm is the "bystander effect" [11] . This phenomenon involves the death of non-HSTK-transfected cells adjacent to HSTK-transfected cells, and allows regression of an entire tumor when only a fraction of the cells comprising the tumor are genetically altered.
.
In this study we examined the effect of adenoviralmediated HSTK gene transfer with subsequent GCV administration on MCA sarcoma tumor growth in vitro and in an in vivo model Qf residual disease. A recombinant replication-deficient adenovirus (AdMLP .HSTK) was constructed with the HSV tk gene downstream ofthe adenovirus majar late promoter. The 1.8-kb cDNA encoding HSV tk was first ligated into an adenovirus shuttle plasmid. The shuttle plasmid based on pBluescript II SK contained a multiple cloning Bite flanked on the 5' end by the left inverted terminal repeat of adenovirus, the E lA enhancer, along with the adenovirus majar late promoter and tripartite leader of adenovirus type 2. On the 3' end of the multiple cloning Bite there was a 3-kb region homologous to adenovirus type 5. A linearized fragment of this recombinant ofthis recombinant plasmid was cotransfected into 293 cells (American Type Culture Collection) along with ClaI cut adenovirus DNA from the E3 deletion mutant Ad-dI327. Single plaques were amplified in 293 celIs. Recombinant virus was screened by PCR amplification for the presence of HSV tk and the absence of the El region to demonstrate successful homologous recombination. A single PCR-positive plaque, AdMLP.HSTK, was amplified in 293 cells and subsequently purified on cesium gradients. Viral stocks in excess of 1010 plaque forming units (pfu) per milliliter of Ad.MLP.HSTK were prepared and titered in 293 celIs [12] .
Construction of AdCMV.Null. A control vector of replication-incompetent adenovirus containing an expression cassette with a CMV promoter without the cDNA insert for HSTK was constructed using the same methods.
Construction of AdCMV.LacZ. A replication incompetent adenoviral vector containing the marker gene, {3-galactosidase, under control of the CMV promoter was constructed as previously described [13] .
Tritiated Thymidine Uptake Studies
Tritiated thyrnidine uptake was utilized as a measure of cellular proliferation. The ability of recombinant adenovirus containing the HSTK gene to affect the viability ofmethylcholanthrene-induced rat rhabdomyosarcoma cells in the presence of GCV (Cytovene, Ganciclovir sodium, Syntex Laboratories, Inc., Palo Alto, CA) was assessed by (3H]thyrnidine uptake studies. The first in viera experiment evaluated the impact of increasing multiplicity of viral infection (m.oi.) with subsequent GCV administration on MCA sarcoma cell DNA synthesis. In triplicate plates, 105 MCA sarcoma cells were incubated in RPMI, 2% fetal calf serum in the presence of AdMLP.HSTK or AdCMV.Null at O, 10,50, and 100 m.oi. for 24 hr. GCV was then added to the infected cells to a concentration of 10 p.g/ml for 48 hr. Cells were incubated for 6 hr with (3H]thyrnidine (0.5 p.Ci/ well; DuPont New England Nuclear, Boston, MA). The medium was aspirated, cells were washed three times with phosphatebuffered saline followed three times with ice-cold 5% trichloroacetic acid. Two hundred proof ethyl alcohol was added to the cells and they were then aspirated. The cells were allowed to air-dry for 15 min and then lysed with 500 p.l 0.1 N NaOH. pH was neutralized with 0.1 N HCl and the amount of (3H]-thyrnidine was quantified in a scintillation counter.
The second in viera experiment determined the effect on MCA sarcoma cells of increasing doses of GCV at an m.oi. of 100 and on MCA cells without prior viral exposure. This experiment was conducted to evaluate GCV toxicity in viera. In triplicate wells, 105 MCA sarcoma cells were infected with either AdMLP .HSTK or AdCMV .Null at an m.oi. of 100 for 24 hr. One group of wells was not exposed to virus. GCV was then added to the wells at concentrations of O, 5, and 10 p.g/ml for 48 hr. (3H]Thyrnidine uptake was evaluated as above.
ally. After betadine skin preparation, a 1-cm skin incision was made ayer the left latissimus muscle. Forceps and scissors were used to create a small cavity in the muscle. A 9-mg MCA sarcoma tumor specimen, excised from a passage animal, was placed into the cavity. A 5-0 silk suture was placed around the tumor to facilitate later identification. The skin was then stapled closed and animals were allowed to recover from anesthesia. Three days were allowed to pass to enable the tumor to implanto On Day 3, animals were anesthetized with pentobarbital sodium, their prior incision was opened with gentle traction, and the incorporated tumor was identified. Under direct vision intratumoral injection of 109 pfu of AdCMV.LacZ in 50 III of viral suspension buffer was performed. The skin was closed and animals were allowed to recover from anesthesia. On Day 5, 48 hr post-AdCMV.LacZ infection, animals were sacrificed via CO2 inhalation and their tumors were excised with al-cm margin of surrounding muscle. The excised flank was fixed in 10% Formalin on ice for 1 hr. The tissue was then placed in X Gal reagent for 4 hr at 37°C. The presence of expressed f3-galactosidase protein was revealed in the development of a blue chromophore. The presence of tumor expressing the f3-galactosidase protein was confirmed visually.
In Vivo Residual Tumor Model
In vivo experiments assessed MCA sarcoma tumor growth in a model of residual disease. Consistent tumor establishment was seen in 170/171 rats implanted with tumor in experiments conducted in our laboratory. This model attempted to approximate clinical postresection sarcoma. On Day O, 41 Fischer rats underwent tumor implantation on Day O as described in the f3-galactosidase expression section. On Day 3, animals were anesthetized with pentobarbital sodium, their prior incision was opened with gentle traction, and the incorporated tumor was identified. Animals were randomized to receive intratumoral injection of AdMLP.HSTK 109 pfu, AdCMV.Null 109 pfu, or viral suspension buffer in 50 III total volume through a 28-gauge needle. Starting on Day 4 and continuing through Day 14, the animals were administered GCV (50 mg/kg) b.i.d. or saline ip. Tumors were excised and weighed on Day 14. The randomization of animals to both intratumoral treatlI1ent and subsequent ip administration of GCV or saline resulted in the creation of five experimental groups. The treatment group consisted of 12 animals that received intratumoral AdMLP.HSTK and then GCV ip. Control groups were designed to evaluate the individual effects of AdMLP .HSTK intratumoral injection, intratumoral viral suspension buffer injection, and GCV ip administration. The effect of combined AdCMV .Null intratumoral injection with subsequent GCV ip administration and the impact of intratumoral viral suspension buffer injection followed by ip saline were algo evaluated.
Animal Care
Animals (male Fischer 344 rats (F344), 200-250 g, Charles River, Kingston, NY) were treated in accordance with the "PrincipIes of Laboratory Animal Care" formulated by the National Society ofMedical Research and the NIH "Guide for the Care and U se of Laboratory Animals" NIH Publication 86-23, revised 1985). Experiments were approved by the Institutional Animal Care and use Committee (lA-CUC), Memorial Sloan-Kettering Cancer Center. AlI rats were allowedaccess to standard laboratory rat chow (Purina Rat Chow, Sto Louis, MO).
Statistical Analysis
Comparison of counts per minute of incorporated tritiated thymidine into MCA sarcoma cells under various conditions and Day 14 tumor weights of animals in different groups was by the nonparametric test to evaluate means, Mann-Whitney U. Significance was defined as P < 0.05.
RESULTS

In Vivo Foreign Gene Expression
To evaluate the ability tQ transfer a foreign gene vía recombinant adenovirus infection into MCA tumor growing in the flank of the Fischer rat, [3-galactosidase express ion was investigated. Two Fischer 344 rats were anesthetized with pentobarbital sodium (Wyeth Laboratories Inc., Philadelphia, FA) 50 mg/kg intraperitone-
In Vitro
In vitro assessment of an antiproliferative effect of AdMLP .HSTK and GCV revealed a significant de-crease in [3H]thymidine incorporation as the multiplicity ofAdMLP.HSTK infectionincreased from O to 100 in the presence of GCV (P < 0.05). There was not a significant decrease in [3H]thymidine incorporation as the m.o.i. of AdCMV.Null increased from O to 100 in the presence of GCV (Fig. 1) .
Increasing GCV concentrations had a significant antiproliferative effect on MCA sarcoma cells infected ,with AdMLP .HSTK. Ganciclovir administration to MCA sarcoma cells without prior viral infection did not result in a significant change in [3H]thymidine incorporation. There was no decrease in [3H]thymidine incorporation of MCA sarcoma cells as GCV was increased from O to 5 ¡.¡,g/ml. A small but significant decrease in [3H]thymidine incorporation was evident in cells infected with AdCMV.Null without GCV and with those treated with 5 and 10 ¡.¡,g/ml GCV (Fig. 2) . In Vivo MCA sarcoma tumor growing in the flanks of the Fisher rat expressed the ,B-galactosidase protein after infection with AdCMV .LacZ. The blue chromophore, resultant from expressed ,B-galactosidase protein and exposure to X-gal reagent, was evident in the tumor nodule. The percentage transfection based on visual estimation from cross sections of tumor after B-Gal staining was between 30 and 50%. This quantification is only an approximation. (Fig. 3) .
The mean tumor weight after excision on Day 14 is illustrated in Table 1 Despite optimal multimodality therapy, the problem of soft tissue sarcoma recurrence persists. This study demonstrated the ability oí adenoviral-mediated prodrug gene therapy to diminish the growth oí sarcoma in vitro and in an in vivo model of residual disease. The ability to treat in vivo sarcoma with a herpes simplex thymidine kinase/ganciclovir prodrug gene therapy strategy is novel.
A scenario where the HSTR/GCV paradigm could be employed clinically is to treat the tumor bed remaining after excision of a soft tissue sarcoma. Local recurrence of sarcoma must occur because of residual tumor ce11s remaining after operation. The tumor bed oí a resected sarcoma has features that may enhance the success of prodrug gene therapy. These characteristics are the míni-mal amount of residual disease that can exist and the superficial nature ofthese residual ce11s. A small amount of residual disease augments the likelihood oí successful therapy. Superficial, nonbulky disease íacilitates adenovirus access to tumor ce11s. The "bystander effect'; may prevent the need for every tumor ce11 to be infected with virus. The induced death of ce11s adjacent to adenovirusinfected ce11s maximizes potential antitumor efficacy.
Evaluating tumor treatment in a model which approximated clinical postresection sarcoma was important. Our model of residual sarcoma was created on the principIe that a tumor must have an established blood supply to achieve rapid growth [14] . In this model of residual disease, MCA sarcoma tumor implanted in the latissimus muscle exhibited rapid consistent growth from Day 3 after implantation. In orde¡ to affect tumor growth and not tumor implantation, treatment with intratumoral adenovirus injection was started on Day 3.
Adenoviral infection and GCV administration exhibited independent antitumor growth effects in our study. Adenovirus infection is known to be cytopathic to cells in vivo. Adenoviral infection elicits a strong infiammatory response ofpredominantly cytotoxic T (CD8+) lymphocytes [8] . Tumor growth inhibition by GCV has been seen in other studies [6] . MCA sarcoma cells were sensitive to elevated doses of GCV in vitro as revealed by decreased [3H]thymidine incorporation. The weight gain of animal s ín the GCV alone group was les s ayer the study length than animals not receiving GCV but not significantly. We chose to treat animals with GCV for 10 days to maximize antitumor effects ofthe combination of GCV and TK, understanding that transgene expression was probably less than 10 days. GCV had an antianabolic effect on the rats that could be related to both daily and total clases r~ceived. We do not have an explanation for the antitumor growth effect.
Clinically, the dimensions of a postresection field after sarcoma excision can measure 20 X 20 cm. The ability to treat residual tumor cells ayer a large field with adenoviral mediated prodrug gene therapy presents a challenge. Further, although treated tumors were smaller at the end of the treatment period, they were not eradicated. We believe this indicates that the treatment was able to kill a proportion of the initial tumor cells but cells remaining after transgene expression stopped and cells not infected with the TK gene grow normally. Optimization of both vector and prodrug are necessary and are currently under study in our laboratory. Strategies include more specifically targeting tumor cells through promoter manipulation and discovering means to enhance immune recognition of tumor. The demonstration ofadenovirus-mediated h:erpes simplex thymidine kinase prodrug gene therapy to inhibit in vivo tumor growth has encouraged us to pursue further study ofthis modality as an adjuvant treatment of human soft tissue sarcoma. AdMLP.HSTR/GCV (n = 12) AdMLP.HSTR/saline (n = 9) AdCMV.NuIVGCV (n = 9) Buffer/GCV (n = 7) Bufferlsaline (n = 4) Note. SEM, standard error of the mean. * p < 0.05 vs all control groups.
